Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Aflibercept for Macular Edema
Recruiting4 awardsPhase 4
Toronto, Ontario
This trial will test the hypothesis that aflibercept intravitreal injections given on a variable dosing regimen is associated with lower aqueous cytokine levels and longer treatment intervals in patients with neovascular age-related macular degeneration, macular edema secondary to retinal vein occlusion and diabetic macular edema.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.